WO1999010746A3 - Method of monitoring blood low molecular weight heparin and heparin - Google Patents

Method of monitoring blood low molecular weight heparin and heparin Download PDF

Info

Publication number
WO1999010746A3
WO1999010746A3 PCT/US1998/017434 US9817434W WO9910746A3 WO 1999010746 A3 WO1999010746 A3 WO 1999010746A3 US 9817434 W US9817434 W US 9817434W WO 9910746 A3 WO9910746 A3 WO 9910746A3
Authority
WO
WIPO (PCT)
Prior art keywords
heparin
molecular weight
low molecular
blood plasma
plasma sample
Prior art date
Application number
PCT/US1998/017434
Other languages
French (fr)
Other versions
WO1999010746A2 (en
Inventor
Hai-Feng Wu
Original Assignee
Univ North Carolina
Wu Hai Feng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Wu Hai Feng filed Critical Univ North Carolina
Priority to AU91145/98A priority Critical patent/AU9114598A/en
Publication of WO1999010746A2 publication Critical patent/WO1999010746A2/en
Publication of WO1999010746A3 publication Critical patent/WO1999010746A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/7454—Tissue factor (tissue thromboplastin, Factor III)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method for determining the concentration of low molecular weight heparin or heparin in a blood plasma sample comprises the steps of: (a) adding a dilute thromboplastin (or tissue factor) solution to a blood plasma sample; and then (b) measuring the time to clot formation in said blood plasma sample. In one embodiment, the dilute thromboplastin (or tissue factor) solution is diluted prior to the adding step so that the time to clot formation in said blood plasma sample is at least 100 seconds when said blood plasma sample contains at least 1 νg/ml of low molecular weight heparin.
PCT/US1998/017434 1997-08-26 1998-08-25 Method of monitoring blood low molecular weight heparin and heparin WO1999010746A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU91145/98A AU9114598A (en) 1997-08-26 1998-08-25 Method of monitoring blood low molecular weight heparin and heparin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92015197A 1997-08-26 1997-08-26
US08/920,151 1997-08-26

Publications (2)

Publication Number Publication Date
WO1999010746A2 WO1999010746A2 (en) 1999-03-04
WO1999010746A3 true WO1999010746A3 (en) 1999-05-20

Family

ID=25443255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/017434 WO1999010746A2 (en) 1997-08-26 1998-08-25 Method of monitoring blood low molecular weight heparin and heparin

Country Status (2)

Country Link
AU (1) AU9114598A (en)
WO (1) WO1999010746A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680177B2 (en) * 2001-12-07 2004-01-20 Cardiovascular Diagnostics, Inc. Low molecular weight heparin assay, system and reagent therefor
US7358337B2 (en) 2002-08-16 2008-04-15 International Technidyne Corporation Assay for low molecular weight heparin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415559A (en) * 1981-02-12 1983-11-15 Eisai Co., Ltd. Anticoagulant
EP0219400A1 (en) * 1985-09-23 1987-04-22 Universite De Technologie De Compiegne Glycopeptides and glycoproteins, any composition containing them, method for their preparation, and anticoagulation applications thereof
EP0511075A1 (en) * 1991-04-23 1992-10-28 Aventis Pharma S.A. Sulfated polysaccharides, process for their preparation, pharmaceutical composition and use thereof
US5625036A (en) * 1991-10-04 1997-04-29 Dade International Inc. Preparation of prothrombin time reagents from recombinant human tissue factor and purified natural and synthetic phospholipids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415559A (en) * 1981-02-12 1983-11-15 Eisai Co., Ltd. Anticoagulant
EP0219400A1 (en) * 1985-09-23 1987-04-22 Universite De Technologie De Compiegne Glycopeptides and glycoproteins, any composition containing them, method for their preparation, and anticoagulation applications thereof
EP0511075A1 (en) * 1991-04-23 1992-10-28 Aventis Pharma S.A. Sulfated polysaccharides, process for their preparation, pharmaceutical composition and use thereof
US5625036A (en) * 1991-10-04 1997-04-29 Dade International Inc. Preparation of prothrombin time reagents from recombinant human tissue factor and purified natural and synthetic phospholipids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
L NORRHEIM, U ABILDGAARD, M L LARSEN, A K LINDAHL: "Involvement of the Extrinsic Pathway in the Activities of Low Molecular Weight Heparins", THROMBOSIS RESEARCH. SUPPLEMENT (14), vol. 14, 1991, pages 19 - 27, XP002094528 *
O NORDFANG, H I KRISTENSEN, S VALENTIN, P OSTERGAARD, J WADT: "The Significance of TFPI in Clotting Assays - Comparison and Combination with Other Anticoagulants", THROMBOSIS AND HAEMOSTASIS, vol. 70, no. 3, 1 September 1993 (1993-09-01), pages 448 - 453, XP002094529 *

Also Published As

Publication number Publication date
AU9114598A (en) 1999-03-16
WO1999010746A2 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
US5051357A (en) Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor
US4692406A (en) Process and a reagent for the simultaneous determination of fibrinogen and fibrinogen fission products in plasma
WO2001057239A3 (en) Reagent test strip for analyte determination
DK0420332T3 (en) A method for determining the endogenous thrombin potential of plasma and blood, as well as a kit for use in the method
EP1503213A3 (en) Detection and determination of the stages of coronary disease
DE69832628D1 (en) RECOMBINANT RABBIT FACTOR BASED PROTHROMBIN TIME REAGENT
CA2346055A1 (en) Method and device for predicting physiological values
JP2003517610A (en) Hematological assays and reagents
EP1316802A3 (en) An ananalyzing method of a blood coagulation reaction
ES2154703T3 (en) PROCEDURE FOR THE SPECIFIC DETECTION OF AN ACTIVATED COAGULATION FACTOR WITH A STABILITY ELEVATED AGAINST ACTIVATED PROTEIN C.
GB1491392A (en) Method for detection of thrombosis and prethrombosis
DK0690991T3 (en) New anticoagulant cofactor activity
EP1162461B8 (en) Automated method for detecting, quantifying and monitoring exogenous hemoglobin in whole blood, plasma and serum
CA2216380A1 (en) Method of determining renal clearances
AU3259999A (en) Method of measuring erythrocyte sedimentation rate (esr) or plasma fibrinogen ofa blood sample
WO1999010746A3 (en) Method of monitoring blood low molecular weight heparin and heparin
WO2001096864A3 (en) A method for detecting a lipoprotein-acute phase protein complex
Inada et al. Faster determination of clottable fibrinogen in human plasma: an improved method and kinetic study.
Shen et al. Differential activities of heparins in human plasma and in sheep plasma. Effects of heparin molecular sizes and sources
WO2002022852A3 (en) Method for measuring antithrombin activity
Soria et al. Severe protein C deficiency in congenital thrombotic disease–description of an immunoenzymological assay for protein C determination
Cinotti et al. Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study
WO1998046993A3 (en) Method for diagnosing cancer by measuring the presence of creatine kinase inhibitor
WO2000050904A8 (en) Test kit for analysing factor viii-splitting protease
Egberg et al. Assay for Hageman factor (factor XII) in human plasma by means of chromogenic substrate for plasma kallikrein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09486429

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA